Cormedix Stock Today
| CRMD Stock | USD 9.98 0.20 2.04% |
Performance14 of 100
| Odds Of DistressLess than 33
|
CorMedix is trading at 9.98 as of the 28th of November 2024, a 2.04 percent increase since the beginning of the trading day. The stock's lowest day price was 9.61. CorMedix has about a 33 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for CorMedix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of March 2010 | Category Healthcare | Classification Health Care |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. The company has 60.68 M outstanding shares of which 6.84 M shares are currently shorted by private and institutional investors with about 4.51 trading days to cover. More on CorMedix
Moving together with CorMedix Stock
| 0.7 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against CorMedix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
CorMedix Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCorMedix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CorMedix's financial leverage. It provides some insight into what part of CorMedix's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
CorMedix (CRMD) is traded on NASDAQ Exchange in USA. It is located in 300 Connell Drive, Berkeley Heights, NJ, United States, 07922 and employs 82 people. CorMedix is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 605.56 M. CorMedix conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 60.68 M outstanding shares of which 6.84 M shares are currently shorted by private and institutional investors with about 4.51 trading days to cover.
CorMedix currently holds about 64.62 M in cash with (38.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57.
Check CorMedix Probability Of Bankruptcy
Ownership AllocationCorMedix holds a total of 60.68 Million outstanding shares. 30% of CorMedix outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CorMedix Ownership Details
CorMedix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Susquehanna International Group, Llp | 2024-06-30 | 367.6 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 321 K | |
| Spinnaker Capital Llc | 2024-06-30 | 175.4 K | |
| Nuveen Asset Management, Llc | 2024-06-30 | 170.3 K | |
| Barclays Plc | 2024-06-30 | 162 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 158.9 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 156.5 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 152.3 K | |
| Steward Partners Investment Advisory, Llc | 2024-06-30 | 142.7 K | |
| Blackrock Inc | 2024-06-30 | 3.6 M | |
| Vanguard Group Inc | 2024-09-30 | 3.1 M |
CorMedix Historical Income Statement
CorMedix Stock Against Markets
CorMedix Corporate Management
| Kaufman Esq | Chief VP | Profile | |
| Joseph MBA | CEO Director | Profile | |
| Donna Ucci | Senior Quality | Profile | |
| Tushar Mukherjee | Senior Operations | Profile | |
| Phoebe Esq | Gen EVP | Profile | |
| Elizabeth BA | Executive Affairs | Profile | |
| Erin Mistry | Executive Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.212 | Quarterly Revenue Growth (0.47) | Return On Assets (0.38) | Return On Equity (0.65) |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.